Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene
- PMID: 7753554
Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene
Abstract
PTC-1, the predominant form of PTC oncogene in human papillary thyroid carcinoma, encodes a fusion protein containing the N-terminus of H4 (D10S170) fused 5' to the ret tyrosine kinase domain. Accordingly, the PTC-1 expression is driven by the H4 gene promoter. Our study showed that H4 is expressed in various human tissues, including thyroid. Furthermore, we have localized the transcriptional start sites of H4 to a region 100 to 190 bp upstream of the translation initiation site (ATG) by primer extension assay, and the H4 promoter to a region within 259 bp upstream of the ATG site by luciferase assay. Interestingly, protein sequence analysis indicated a potential coiled-coil domain in the N-terminal region of H4. Indeed, oligomerization was demonstrated by an in vitro assay with recombinant proteins containing this region. As dimerization is considered to be a crucial step for receptor tyrosine kinase activation, we hypothesize that both unscheduled expression of ret tyrosine kinase and constitutive oligomerization of PTC-1 proteins are responsible for PTC-1 transforming activity in thyroid.
Similar articles
-
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.Oncogene. 1994 Feb;9(2):509-16. Oncogene. 1994. PMID: 8290261
-
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.Oncogene. 2004 Jan 8;23(1):109-21. doi: 10.1038/sj.onc.1206981. Oncogene. 2004. PMID: 14712216
-
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.Hum Mol Genet. 1995 Dec;4(12):2313-8. doi: 10.1093/hmg/4.12.2313. Hum Mol Genet. 1995. PMID: 8634704
-
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement.Recent Results Cancer Res. 1998;154:248-64. doi: 10.1007/978-3-642-46870-4_16. Recent Results Cancer Res. 1998. PMID: 10027005 Review.
-
[Rearrangement of the RET gene in papillary thyroid carcinoma].Wiad Lek. 2001;54 Suppl 1:64-71. Wiad Lek. 2001. PMID: 12182064 Review. Polish.
Cited by
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.Int J Oncol. 2017 Jul;51(1):145-157. doi: 10.3892/ijo.2017.3994. Epub 2017 May 11. Int J Oncol. 2017. PMID: 28498409 Free PMC article.
-
Identification of targetable FGFR gene fusions in diverse cancers.Cancer Discov. 2013 Jun;3(6):636-47. doi: 10.1158/2159-8290.CD-13-0050. Epub 2013 Apr 4. Cancer Discov. 2013. PMID: 23558953 Free PMC article.
-
Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control.PLoS One. 2012;7(2):e31007. doi: 10.1371/journal.pone.0031007. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363533 Free PMC article.
-
Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling.Mol Cell Proteomics. 2009 Nov;8(11):2487-99. doi: 10.1074/mcp.M800544-MCP200. Epub 2009 Aug 1. Mol Cell Proteomics. 2009. PMID: 19648646 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials